• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A pilot study of mitomycin-C/5-fluorouracil infusion combined with split course radiation therapy for carcinomas of the larynx and hypopharynx.

作者信息

Keane T J, Harwood A R, Beale F A, Cummings B J, Payne D G, Elhakim T, Rawlinson E

出版信息

J Otolaryngol. 1986 Oct;15(5):286-8.

PMID:3095563
Abstract

Fifty-seven patients with advanced squamous carcinoma of the larynx and hypopharynx were entered on a pilot study of initial therapy using split course radiation therapy combined with simultaneous chemotherapy using mitomycin-C and 5-fluorouracil. The treatment was well tolerated with 90% of patients completing their planned radiation treatment. Seventy percent of this group completed their planned chemotherapy. Significant hematological toxicity was not observed. Survival and loco regional control at one and two years of follow-up were considered at least comparable to that achieved with conventional single-course radical radiation therapy as primary treatment. Based on these results a randomized trial of this radiation-chemotherapy regimen compared to radiation therapy alone as initial therapy is in progress.

摘要

相似文献

1
A pilot study of mitomycin-C/5-fluorouracil infusion combined with split course radiation therapy for carcinomas of the larynx and hypopharynx.
J Otolaryngol. 1986 Oct;15(5):286-8.
2
Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients.顺铂和5-氟尿嘧啶诱导化疗后序贯放化疗或单纯放疗治疗喉和下咽局部晚期可切除癌:45例患者的单中心研究结果
Head Neck. 2005 Jan;27(1):15-21. doi: 10.1002/hed.20107.
3
A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma.一项关于放射治疗与分割疗程放射治疗联合丝裂霉素C和5-氟尿嘧啶作为晚期喉和下咽鳞状细胞癌初始治疗方法的随机试验。
Int J Radiat Oncol Biol Phys. 1993 Mar 15;25(4):613-8. doi: 10.1016/0360-3016(93)90006-h.
4
Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.喉和下咽鳞状细胞癌的区域转移延迟、远处转移及第二原发性恶性肿瘤
Laryngoscope. 2001 Jun;111(6):1079-87. doi: 10.1097/00005537-200106000-00028.
5
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.头颈部未切除局部晚期鳞状细胞癌超分割与加速放疗及放化疗联合方案的荟萃分析
BMC Cancer. 2006 Jan 31;6:28. doi: 10.1186/1471-2407-6-28.
6
Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.基于顺铂的联合治疗方案用于肛管癌:具有更宽的治疗指数。
Cancer. 2003 Mar 1;97(5):1195-202. doi: 10.1002/cncr.11161.
7
Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial.肝动脉化疗栓塞联合5-氟尿嘧啶全身输注及大剂量亚叶酸钙治疗转移性结直肠癌患者:西南肿瘤协作组的一项试点试验。
Cancer. 1999 Sep 1;86(5):775-81.
8
Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08.肛管癌同步放化疗中的剂量递增:RTOG 92-08的初步结果
Cancer J Sci Am. 1996 Jul-Aug;2(4):205-11.
9
[Induction chemotherapy and larynx preservation: is such practice useful?].[诱导化疗与喉保留:这种做法有用吗?]
Bull Cancer. 2002 Apr;89(4):411-7.
10
Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx.顺铂、5-氟尿嘧啶、甲氨蝶呤和亚叶酸钙同步放化疗用于晚期可切除喉和下咽鳞状细胞癌患者
Acta Otolaryngol. 2006 Apr;126(4):408-13. doi: 10.1080/00016480500401019.